Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hollis

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 20, 2019
Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region ElementsRichard A Morgan, Mildred J Unti, Bamidele Aleshe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 14, 2016
CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cellsMegan D Hoban, Dianne Lumaquin, Caroline Y Kuo, et al.
Blood Advances|April 20, 2026
Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell DiseaseChattip Prueksapraopong, Augustine Fernandes, Beatriz Campo Fernandez, et al.
Journal for Immunotherapy of Cancer|August 2, 2020
Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141<sup>+</sup> dendritic cells to activate naïve and memory NY-ESO-1-specific CD8<sup>+</sup> T cellsKelly-Anne Masterman, Oscar L Haigh, Kirsteen M Tullett, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2019
Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor TemplatesZulema Romero, Anastasia Lomova, Suzanne Said, et al.
Transplantation Proceedings|June 24, 1998
Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppressionR M Ghobrial, S Colquhoun, H Rosen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 22, 2013
Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiencyDenise A Carbonaro, Lin Zhang, Xiangyang Jin, et al.
The Journal of Clinical Investigation|July 19, 2013
β-globin gene transfer to human bone marrow for sickle cell diseaseZulema Romero, Fabrizia Urbinati, Sabine Geiger, et al.
Blood|March 4, 2015
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cellsMegan D Hoban, Gregory J Cost, Matthew C Mendel, et al.
Blood|May 11, 2021
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiencyBryanna Reinhardt, Omar Habib, Kit L Shaw, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 20, 2019
Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region ElementsRichard A Morgan, Mildred J Unti, Bamidele Aleshe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 14, 2016
CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cellsMegan D Hoban, Dianne Lumaquin, Caroline Y Kuo, et al.
Blood Advances|April 20, 2026
Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell DiseaseChattip Prueksapraopong, Augustine Fernandes, Beatriz Campo Fernandez, et al.
Journal for Immunotherapy of Cancer|August 2, 2020
Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141<sup>+</sup> dendritic cells to activate naïve and memory NY-ESO-1-specific CD8<sup>+</sup> T cellsKelly-Anne Masterman, Oscar L Haigh, Kirsteen M Tullett, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2019
Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor TemplatesZulema Romero, Anastasia Lomova, Suzanne Said, et al.
Transplantation Proceedings|June 24, 1998
Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppressionR M Ghobrial, S Colquhoun, H Rosen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 22, 2013
Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiencyDenise A Carbonaro, Lin Zhang, Xiangyang Jin, et al.
The Journal of Clinical Investigation|July 19, 2013
β-globin gene transfer to human bone marrow for sickle cell diseaseZulema Romero, Fabrizia Urbinati, Sabine Geiger, et al.
Blood|March 4, 2015
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cellsMegan D Hoban, Gregory J Cost, Matthew C Mendel, et al.
Blood|May 11, 2021
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiencyBryanna Reinhardt, Omar Habib, Kit L Shaw, et al.
Pageof 11